S1 Pharmaceuticals Announces New Executive Management and Scientific Advisory Board Appointments
Emerging Women's Sexual Health BioPharma Strengthens Position in Marketplace with New Additions
24 Apr, 2012, 05:00 ET
JERSEY CITY, N.J., April 24, 2012 /PRNewswire/ -- S1 Pharmaceuticals, Inc., a developer of therapeutics for disorders of women's sexual health, announced today an executive management addition and Scientific Advisory Board appointment that strengthen and expand the Company's leadership:
- John F. Kaufmann, M.B.A. was appointed as the Company's Chief Financial Officer.
- Cindy M. Meston, Ph.D. was appointed as a member of the Company's Scientific Advisory Board of Directors.
"Mr. Kaufman brings deep financial experience that will guide our company as it grows and matures," said Nicolas G. Sitchon, CEO of S1 Pharmaceuticals. "We are in good hands with a professional of his caliber among our ranks."
Mr. Kaufmann is a finance executive with experience managing three startup portfolio companies, including one at $500MM invested of Fidelity Investments Corp. His experience also includes a similar role with Laureate, a leading multinational higher education holding company. Mr. Kaufmann's main expertise is in startup and early-growth stage company finance, including valuations, raising capital, and managing relations with institutional investors and venture capital partners. Mr. Kaufmann received his M.B.A. in Finance from Boston University and his B.A. in History from Dartmouth College.
"S1 Pharmaceuticals represents an exciting opportunity in an innovative field, and I look forward to working with Mr. Sitchon and the rest of the management team to help the company realize its full potential," said Mr. Kaufmann.
Cindy M. Meston, Ph.D., is a past President of the International Society for the Study of Women's Sexual Health (ISSWSH), and an active member of the International Academy of Sex Research (IASR) and the Society for the Scientific Study of Sexuality (SSSS). Her book, Why Women Have Sex, which was published in 2009 with co-author David Buss, has been translated into nine foreign languages. She has published over 100 peer-reviewed scientific articles and given over 200 presentations both nationally and internationally on sexuality topics that span the areas of nervous system regulation of women's sexual arousal, drug effects on sexual response, the development of sexual self-views, body image influences on sexual functioning, monogamy, treatments for women with a history of childhood sexual abuse, and ethnic and religious influences on sexual behavior. Her research has appeared in the New York Times, Scientific American, Newsweek, and numerous women's and health magazines. Cindy M. Meston received her Ph.D. in Clinical Psychology from the University of British Columbia, a postdoctoral fellowship in Sexual and Reproductive Medicine at the University of Washington, School of Medicine, and a postdoctoral fellowship from the Social Science Research Council, Ford Foundation.
"Dr. Meston is one of the most distinguished voices in the field of women's sexual health," said Mr. Sitchon. "We are thrilled to have her insights and contributions helping to shape our decision-making. As a company, we are one step closer to developing a safe and effective treatment for female sexual desire disorders."
About S1 Pharmaceuticals, Inc.
S1 is an early-stage biopharmaceutical developer of therapeutics for disorders of Women's Sexual Health. The most common type of Female Sexual Dysfunction (FSD) is a distressing loss of libido known as Hypoactive Sexual Desire Disorder (HSDD). S1 is developing its lead product, Lorexys, as an oral drug and will seek to demonstrate that Lorexys can be the first safe and effective treatment approved by the FDA for HSDD in women.
SOURCE S1 Pharmaceuticals, Inc.
Share this article